Brain Slice Explants to Predict Drug Response in Brain Tumors

Central Nervous System Tumor Clinical Trial

Official title: A Feasibility Study to Determine if a Novel Patient-derived Explant Platform Can Produce Drug Sensitivity Scores Within a Clinically Relevant Time Frame in Patients With CNS Tumors

Status Recruiting

Clinical Trial Summary

This biospecimen collection study will evaluate the feasibility of engrafting and testing resected Central nervous system (CNS) tumors tumor tissue ex vivo to estimate drug response, in pediatric and adult subjects. CNS tumors display remarkable heterogeneity and unfortunately there are no reliable precision oncology platforms that can identify the most effective therapy for each patient. Recent work has demonstrated the success of functional precision oncology platforms using patient-derived explant (PDE) at predicting drug response in various cancers. Since PDEs maintain important aspects of tumor heterogeneity they may prove effective as functional models for CNS tumors. The purpose of this study is to explore the feasibility of using a novel PDE platform to generate drug sensitivity scores from patients with central nervous system tumors in Pediatric and adult subjects having low- or high-grade CNS tumors resected. The secondary objective is to estimate the proportion of successfully scaled PDEs generated per given tumor size.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Central Nervous System Neoplasms
• Central Nervous System Tumor
• Nervous System Neoplasms

• NCT number: NCT05978557
• Study type: Observational
• Source: UNC Lineberger Comprehensive Cancer Center
• Contact: Devin McCarthy
• Phone: 919-966-7654
• Email: devin_mccarthy@med.unc.edu
• Status: Recruiting
• Start date: July 27, 2023
• Completion date: March 1, 2028